Vince Bush, MCCR Board Member

It is unfortunately common to hear that someone we know, whether it be a spouse, family member, friend, colleague, or neighbor, has received a cancer diagnosis. We are aware of the usual methods of treatment, such as chemotherapy, surgery and radiation, each of which has its benefits, but also invasive and tiring.

However, serving on the board of Mary Crowley Cancer Research (MCCR), I have gained knowledge that I believe every cancer patient should be aware of...

Dr. James Strauss,

Clinical Scientific Director

The recent FDA approval for futibatinib was based on a clinical study that was opened in our clinic at Mary Crowley Cancer Research.

The drug tested was designed to inhibit an abnormal growth signal that occurs in some cases of a cancer called intrahepatic cholangiocarcinoma. This cancer is a tumor of the bile ducts within the liver. The tumor is difficult to detect in its early stages. Advanced or metastatic tumors of this type are treated with chemotherapy but usually become resistant...